Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

V. Desai, Ami; Robinson, Giles; Gauvain, Karen; M. Basu, Ellen; E. Macy, Margaret; Maese, Luke; Whipple, Nicholas; J. Sabnis, Amit; H. Foster, Jennifer; Shusterman, Suzanne; Yoon, Janet; Weiss, Brian; S Abdelbaki, Mohamed; E. Armstrong, Amy; F. Cash, Thomas; A. Pratilas, Christine; Corradini, Nadège; V. Marshall, Lynley; Farid‐Kapadia, Mufiza; Chohan, Saibah; Devlin, Clare; Meneses‐Lorente, Georgina; K. Cardenas, Alison; E. Hutchinson, Katherine; Bergthold, Guillaume; Caron, Hubert; Chow Maneval, Edna; Gajjar, Amar; Fox, Elizabeth

doi:10.1093/neuonc/noac087

Public

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Published in Neuro-Oncology • Apr 8, 2022

Authors:

Ami V. Desai

Giles Robinson

Karen Gauvain

Abstract

BACKGROUND: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non-small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investiga...

Subject

ROS1

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!